Aion Therapeutic Inc.

Aion Therapeutic Inc.

Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways

LONDON and TORONTO, May 18, 2021 - Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased ... Read More...

Aion Therapeutic Amends Convertible Debentures

Toronto, Ontario--(Newsfile Corp. - October 30, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that the Company has entered into a convertible debenture extension and amendment agreement (the "Amending Agreement") dated October 29, 2020 with Quinsam Capital Corporation (the "Lender"). The A... Read More...

Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas as Chief Science Officer

Dr. Fritsche has also been appointed Chief Science Officer of AI Pharma, a wholly-owned subsidiary of Aion TherapeuticToronto, Ontario--(Newsfile Corp. - September 10, 2020) - Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas... Read More...